Biocon stock carries 10 percent Q1 revenue growth into October

Published on 10/07/2026 at 00:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Biocon stock was last at INR 369.10 on October 6, 2026, while Q1 FY27 revenue rose 10 percent to INR 43.36 billion. Axis Securities set a INR 424 target on September 19.

Biocon, INE376G01013, Illustration mit AI erstellt.

Biocon stock (ISIN INE376G01013) was last at INR 369.10 on the NSE on October 6, 2026, with a market capitalization of INR 504.3 billion. The latest reported quarter showed revenue growth, a sharp profit increase and a mixed operating picture across the group's businesses.

Q1 revenue rises 10 percent

According to Alpha Inflection, Biocon's consolidated revenue reached INR 43.36 billion in Q1 FY27, the quarter ended June 30, 2026, up 10 percent from the year-earlier period. The same results context put EBITDA margin at 20.8 percent and reported net profit at INR 1.411 billion.

The profit comparison is the sharper signal: Alpha Inflection reported a 355 percent year-over-year increase in net profit for Q1 FY27. Revenue also fell 4 percent from the preceding quarter, so the annual growth rate does not remove the sequential volatility from the picture.

Biosimilars lead the mix

Biosimilars revenue increased 16 percent year over year in Q1 FY27, while the generics business returned to profitability, according to Alpha Inflection on September 27, 2026. Services moved in the opposite direction, making the business mix more important than the consolidated revenue figure alone.

Analyst attention is centered on capacity and margins. DSIJ reported on September 19, 2026 that Axis Securities rated Biocon Buy and set a target price of INR 424, citing insulin capacity expansion, biosimilar launches and lower interest costs.

Stock sits below yearly high

At INR 369.10 on October 6, 2026, Biocon stock stood below its 52-week high of INR 447.15 and above its 52-week low of INR 337.70. The session range was INR 366.60 to INR 371.00, with volume of 4,645,858 shares, giving investors a current market reference alongside the Q1 operating figures.